Sai Life Sciences , a rapidly growing Contract Research, Development, and Manufacturing Organization (CRDMO), has announced plans to significantly expand its research and development capabilities. The company has broken ground on a new CMC Process R&D Center at its integrated R&D campus in Hyderabad, marking a major step in its growth strategy.

Expansion Details

The new facility, expected to be operational by September 2026, is designed to double the company's Process R&D capacity. Here are the key features of the upcoming center:

Strategic Importance

This expansion is part of Sai Life Sciences' planned capital expenditure, driven by increasing demand for late-stage development programs and scalable CMC capacity. The investment reflects the company's strong business momentum and expanding engagement with global pharmaceutical and biotech partners.

Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences, emphasized the strategic importance of this expansion, stating, "As our partners seek greater speed, flexibility, and scientific depth, we are scaling our capabilities to move programs faster and more efficiently through the development continuum."

New Capabilities

The new center introduces several new capabilities to Sai Life Sciences' portfolio:

• Peptide development
• Oligo intermediates & linkers development
• Formulation development
• Early-phase clinical supplies

These additions are expected to enhance the company's ability to support both Full-Time Equivalent (FTE) and Dedicated Project Capacity (DPC) engagement models, enabling more flexible collaboration with global innovators from early development to late-stage CMC programs.

Industry Impact

This expansion positions Sai Life Sciences to better meet the growing demand for end-to-end, partnership-driven solutions in the pharmaceutical and biotech industries. By combining scientific excellence with execution agility, the company aims to accelerate the discovery, development, and commercialization of small molecules and emerging modalities.

As the pharmaceutical landscape continues to evolve, with timelines becoming increasingly compressed, Sai Life Sciences' investment in this new CMC Process R&D Center demonstrates its commitment to staying at the forefront of the industry and delivering innovative solutions to its partners worldwide.

Sai Life Sciences , a leading Contract Research, Development, and Manufacturing Organization (CRDMO), has marked a significant milestone in its growth strategy with the inauguration of a new dedicated facility for veterinary API production. The company officially opened Unit VI on September 18, 2025, in Bidar, India, strategically located alongside its flagship API manufacturing site, Unit IV.

Expansion into Veterinary APIs

The new Unit VI facility represents Sai Life Sciences' strategic move into the burgeoning veterinary pharmaceutical market. Designed to meet stringent safety, sustainability, and regulatory compliance standards, the facility aims to produce high-quality APIs for veterinary applications. This expansion positions the company to offer efficient and scalable manufacturing solutions to leading global animal health companies.

Strategic Location and Capabilities

Situated adjacent to the company's existing Unit IV in Bidar, Karnataka, the new facility leverages Sai Life Sciences' established infrastructure and expertise. The strategic location allows for operational synergies and streamlined processes, enhancing the company's overall manufacturing capabilities.

Meeting Growing Demand

Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences, emphasized the significance of this investment, stating, "This investment strengthens our ability to meet the growing global demand for high-quality veterinary pharmaceuticals while ensuring the highest standards of innovation, efficiency, and sustainability. We are proud to support our innovator partners in their mission of offering reliable solutions that enhance animal well-being."

Advanced Technologies and Compliance

Unit VI incorporates advanced technologies, robust supply chain management, and best-in-class safety practices. These features ensure reliable and cost-effective manufacturing of animal health APIs, aligning with the company's reputation for advanced process capabilities, operational excellence, and stringent quality standards.

Market Opportunity

The expansion into veterinary APIs comes at a time when the market presents significant growth opportunities. Increasing demand for veterinary medicines and advancements in animal healthcare are driving this sector's growth. Sai Life Sciences' investment in this specialized facility aligns with its strategic vision to enhance its offerings in niche, high-value segments of the pharmaceutical industry.

Company Profile

With over two decades of manufacturing expertise, Sai Life Sciences has established itself as a trusted partner in API production. The company works with over 300 global innovator pharma and biotech companies, accelerating the discovery, development, and commercialization of NCE small molecule programs. Sai Life Sciences employs over 3,400 people across its facilities in India, UK, and USA.

Investor Relations

In a related development, Sai Life Sciences has scheduled meetings with several prominent investment firms on September 24, 2025. The company will engage with representatives from William Blair Investment Management, Orbimed Advisors India, Dymon Asia, Norges Bank Investment Management, and Amansa Capital in Hyderabad. This engagement with investors underscores the company's commitment to transparency and its growing profile in the global pharmaceutical industry.

As Sai Life Sciences continues to expand its capabilities and market reach, the new veterinary API facility in Bidar marks a significant step in the company's journey to becoming a comprehensive partner for the global pharmaceutical industry, now extending its expertise into the animal health sector.